Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MobiPrep is a low-volume, polyethylene glycol (PEG)-based osmotic laxative used for bowel cleansing prior to colonoscopy or other medical procedures requiring a clean colon. It is a combination product containing macrogol 3350 (PEG), anhydrous sodium sulfate, sodium chloride, potassium chloride, ascorbic acid, and sodium ascorbate. The mechanism of action involves the osmotic effect of PEG and sodium sulfate, which retain water in the intestinal lumen, thereby increasing stool volume and stimulating peristalsis. The inclusion of ascorbic acid and sodium ascorbate provides an additional osmotic load, which allows for effective bowel cleansing with a significantly reduced volume of fluid (typically 2 liters) compared to traditional 4-liter PEG solutions. It is primarily developed and marketed in South Korea by Taejoon Pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MobiPrep.